Store-operated calcium entry (SOCE) 
INTRODUCTION
Modulation of intracellular Ca 2þ concentrations [Ca 2þ ] i is an important signal transduction mechanism to regulate the function of immune cells (Feske, 2007; Vig & Kinet, 2009 ). In T cells, antigen binding by the T-cell receptor (TCR) results in a [Ca 2þ ] i rise that is due to Ca 2þ release from the endoplasmic reticulum (ER) and Ca 2þ influx across the plasma membrane through Ca 2þ release-activated Ca 2þ (CRAC) channels. Opening of CRAC channels is required for sustained [Ca 2þ ] i increases, activation of Ca 2þ dependent signalling molecules and T-cell effector functions (Feske, 2007) . The pore of the CRAC channel is formed by ORAI1 proteins in the plasma membrane. Channel opening and Ca 2þ influx results from the binding of two proteins, stromal interaction molecules (STIM) 1 and STIM2, to ORAI1. STIM proteins are located in the membrane of the ER, where they sense [Ca 2þ ] ER using an EF hand Ca 2þ binding domain in their N terminus. Ca 2þ release from the ER causes oligomerization of STIM molecules, their translocation to the plasma membrane and binding to ORAI1. This process is called store-operated Ca 2þ entry (SOCE) and constitutes the predominant Ca 2þ influx pathway in lymphocytes (Feske, 2007) . Both STIM1 and STIM2 are required for SOCE in T cells. Lossof-function or null mutations in the human STIM1 gene abolish Ca 2þ influx in T cells and cause immunodeficiency in affected patients (Byun et al, 2010; Fuchs et al, 2012; Picard et al, 2009) . Similarly, deletion of murine Stim1 severely impairs SOCE and the function of T cells (Oh-Hora et al, 2008) , most evident in the inability of STIM1-deficient CD4 þ T cells to mediate inflammation in animal models of autoimmune disease McCarl et al, 2010; Schuhmann et al, 2010) . The role of SOCE in CD8 þ T cell-mediated immunity in vivo is less well defined.
SOCE-deficient patients with mutations in STIM1 or ORAI1 genes are susceptible to recurrent viral infections, potentially due to impaired CD8 þ T-cell function and elimination of virus-infected cells (Feske, 2009 (Feske, , 2010 . In several cases, chronic viral infections in ORAI1-and STIM1-deficient patients have caused Epstein-Barr virus (EBV)-positive B cell lymphoma and Human herpesvirus (HHV) 8-associated Kaposi sarcoma (Byun et al, 2010; Fuchs et al, 2012) , suggesting that SOCE may be required for antitumour immunity by CD8 þ T cells.
CD8
þ T cells are cytotoxic lymphocytes (CTLs) that play an important role in antitumour immune responses because of their ability to kill tumour cells (Frey & Monu, 2008; Schwarz et al, 2012) . Infiltration of tumours with CD8 þ T cells positively correlates with survival, for instance in patients with small cell lung cancer (Kawai et al, 2008) . CTLs recognize tumour cells through their T-cell antigen receptor and CD8 coreceptor which bind to (tumour) peptide-MHC class I complexes on the surface of tumour cells. TCR engagement activates several CTL effector functions that contribute to antitumour immunity (Chavez-Galan et al, 2009) . One is the release of perforin and granzyme from cytolytic granules, which induce caspasedependent apoptotic cell death in their target cells (Voskoboinik et al, 2010) . Early evidence suggested that CTL effector functions depend on Ca 2þ as human CTLs exhibited Ca 2þ influx upon immune synapse formation with tumour cells (Lyubchenko et al, 2001 ). Furthermore, chelating extracellular Ca 2þ with EGTA impaired the ability of murine CTLs to kill lymphoma cells (MacLennan et al, 1980) . A possible explanation is the dependence of CTLs on Ca 2þ influx to form immune synapses and to release cytolytic granules (Pores-Fernando & Zweifach, 2009 ). However, genetic evidence for a role of CRAC channels in the cytolytic function of CTLs is missing. In natural killer (NK) cells, degranulation and cytotoxicity depend on SOCE as the lytic function of NK cells from an ORAI1-deficient patient was strongly reduced. By contrast, the cytolytic function of CD8 þ T cells from a STIM1-deficient patient was normal despite strongly reduced SOCE (Fuchs et al, 2012) . Other mechanisms contribute to the antitumour immune function of CD8 þ T cells including their ability to express of death receptor ligands FasL and TRAIL (Chavez-Galan et al, 2009; Mahmood & Shukla, 2009) and to secrete IFN-g and TNF-a (Calzascia et al, 2007) . Importantly however, the roles of SOCE in these CD8 þ T-cell effector functions and especially in tumour immunosurveillance in vivo are not understood. To determine if CRAC channels control CD8 þ T-cell functions in the context of antitumour immunity, we used mice with T cellspecific deletion of Stim1 and Stim2 genes (Stim1 fl/fl Stim2 fl/fl Cd4Cre, or DKO for simplicity) that lack SOCE in CD4 þ and CD8 þ T cells (Oh-Hora et al, 2008) . We found that SOCE in T cells curtails the growth of tumour allografts and that STIM1 and STIM2 deficient CTLs fail to prevent tumour cell engraftment. SOCE was not required for the expansion of tumour specific CTLs and their infiltration of tumours, but was necessary for lytic granule exocytosis, tumour cell killing and production of IFN-g and TNF-a. Collectively, our data support an important role of SOCE in antitumour immune responses. (Fig 1A) , which have been shown to increase antitumour CD8 þ T-cell responses in mice and in human patients, resulting in attenuated murine tumour growth (Ataera et al, 2011; Rech et al, 2012 ) and differentiated into CTLs for 8 days in vitro. To inhibit SOCE, CTLs were incubated with the longacting, selective CRAC channel inhibitor BTP2 for the last 18 h before adoptive transfer into tumour bearing mice (Fig 2C) . Treatment of Ova-specific CTLs with 1 mM BTP2 resulted in almost complete inhibition of SOCE, which persisted for at least 1 h after BTP2 had been removed from cells (Fig 2D) . To test if SOCE-deficient CTLs are able to home to TDLN, we coinjected CTLs treated with either BTP2 or DMSO (control) at a 1:1 ratio into mice with established B16-Ova melanomas. One hour after injection, no difference in the ratio of BTP2-and DMSO-treated CTLs was observed in TDLN (Fig 2E) . BTP2-treated CTL homed to TDLN to the same extent as DMSO-treated CTL, indicating that SOCE is not required for CTL migration. Collectively, our data show that SOCE is not required for the priming and expansion of tumour antigen-specific CTLs or their migration into TDLN.
RESULTS

SOCE in CD8
CD4 þ CD25 þ FOXP3 þ regulatory T (Treg) cells
SOCE in CTLs prevents engraftment of tumour cells
To understand why DKO mice fail to control tumour growth (Fig 1) Fig 3A) . In contrast to experiments described above, in this setting all differences observed between mice injected with WT D. Calcium influx after treatment with BTP2. CTLs from WT OT-1 mice were generated as described in (C) and treated for 18 h with BTP2 or DMSO, labelled with Fura-2-AM in the absence of BTP2 (30 min and DKO CTLs are due to CD8 þ T-cell intrinsic effects of SOCE.
We confirmed that the number of Ova-specific T cells and TCR expression level are comparable between CTLs derived from WT and DKO OT-1 mice (Fig 3B) . To exclude that lack of SOCE in CTLs from DKO OT-1 mice affected their survival in vivo, we determined the number of CD8 þ CD45.2 þ CTLs in the blood of recipient mice 5 days after adoptive transfer. In fact, the frequencies of STIM1/2-deficient Ova-specific CTLs were higher than those of wildtype CTLs (Fig 3C) . Importantly, when we compared the growth of B16-Ova melanomas in mice that had received either no CTLs, wildtype CTLs or DKO CTLs, we observed a complete failure of STIM1/2-deficient CTLs to prevent tumour progression (Fig 3D) . 14 days after melanoma and CTL injection, no tumours were detectable in mice that had received wildtype CTLs, whereas tumour growth was similar in mice that were injected with STIM1/2-deficient CTLs or no CTLs at all. This failure of STIM1/2-deficient CTLs to prevent tumour engraftment was not due to their reduced number since no significant differences of transferred CTLs could be found in the spleens ($1. OT-1 mice into CTLs in vitro and cocultured them with EG7-Ova cells that are derived from the murine T-cell lymphoma EL4 (Moore et al, 1988) . STIM1/2-deficient Ova-specific CTL showed a 29-64% reduction in their cytotoxic function compared to wildtype CTL depending on the CTL:EG7 ratio (Fig 4A) . In addition, CTLs from Stim1 fl/fl Stim2 fl/fl Cd4Cre OT-1 mice had a severe defect in the production of IFN-g and TNF-a compared to wildtype CTLs when stimulated with either PMA/ionomycin or Ova peptide in vitro (Fig 4B) . To confirm these findings and analyse the quantitative relationship between SOCE and CTL function, we inhibited CRAC channel function with increasing concentrations of BTP2. 10 nM and 100 nM BTP2 partially inhibited SOCE in CTLs, whereas 300 nM and 1 mM BTP2 almost completely abolished SOCE (Fig 4C) (Fig 4D) .
CTLs utilize a number of mechanisms to kill tumour cells including release of cytolytic granules containing perforin and granzyme B, as well as the expression of the death receptor ligand FasL that interact with the Fas receptors on target cells, respectively. Inhibition of CRAC channel function with BTP2 significantly inhibited the exocytosis of lytic granules by Ovaspecific CTLs in response to coincubation with EG7-Ova cells as measured by cell surface expression of CD107a (Fig 5A) . By contrast, the expression of proteins contained in lytic granules, Granzyme B and Perforin, was not dependent on SOCE (Fig 5B  and C) A. CTL degranulation. Ova specific CTLs from WT OT-1 mice were treated with BTP2 for 14 h and analysed for CD107a (LAMP-1) expression by flow cytometry after coincubation for 90 min with EG7-Ova cells at a 1:2 ratio (same experiment as in Fig 4D) . Representative dot plots and means AE SEM of n ¼ 3 independent experiments performed in duplicates. Relative degranulation for each experiment was calculated as: ÃÃ p < 0.01. E. IFN-g and TNF-a production. CTLs were treated with 1 mM BTP2 (or DMSO) for 14 h and cocultured with EG7-Ova cells at a 1:2 ratio for 6 h in the presence of Brefeldin A. IFN-g and TNF-a production were analyzed by flow cytometry. Representative dot plots and means AE SEM of n ¼ 2 independent experiments performed in duplicates. (that lack all SOCE) following strong stimulation with PMA/ ionomycin or Ova peptide (unpublished observations). Inhibition of SOCE with BTP2 also resulted in a moderate but significant decrease in the expression of FasL on the surface of OT-1 CTLs after coculture with EG7-Ova cells (Fig 5D) . This is consistent with reports that the transcription of FasL is regulated by NFAT, a Ca 2þ dependent transcription factor (Rengarajan et al, 2000; Wang et al, 2011) . Apart from contact dependent cytotoxicity, CTL control tumour growth by secretion of TNF-a and IFN-g (Calzascia et al, 2007) . Inhibition of SOCE in OT-1 CTLs with BTP2 severely impaired the production of both cytokines after coculture with EG7-Ova cells (Fig 5E) . Collectively, our data show that CRAC channel function and SOCE mediate important effector functions of cytotoxic T cells that are required for killing of tumour cells.
DISCUSSION
Taken together, our results show for the first time that activation of CRAC channels by STIM1 and STIM2 proteins is essential for tumour immunosurveillance by CD8 þ T cells. STIM1 and STIM2
are dispensable for the priming, expansion and homing of tumour antigen-specific CTLs. However, they are crucial for cytolytic effector functions of CTLs, especially their ability to produce IFN-g and TNF-a, to release perforin-containing cytolytic granules, to induce FasL and to kill tumour cells. Our data confirm previous observations of decreased degranulation and cytotoxicity by CTLs after chelating extracellular Ca 2þ with EGTA (MacLennan et al, 1980) . However, the channels mediating the Ca 2þ influx required for the cytolytic function of tumour specific CTLs were not well defined. Our data using conditional knockout mice with T-cell specific deletion of Stim1 and Stim2 genes unambiguously show that the Ca 2þ influx required for antitumour immunity by CTLs is dependent on CRAC channels, which are activated by STIM1 and STIM2. As a consequence, CTL lacking both Stim1 and Stim2 genes and therefore CRAC channel function failed to control the growth of melanoma and colon carcinoma cells and to prevent tumour engraftment. The role of SOCE in T-cell mediated antitumour immunity is summarized in Fig 5F . Impaired antitumour immunity and CTL function in Stim1 fl/fl Stim2 fl/fl Cd4Cre mice likely explain why human patients lacking SOCE due to mutations in the CRAC channel genes ORAI1 and STIM1 develop virus-associated malignancies such as EBV þ B cell lymphoma and HHV8 þ Kaposi sarcoma (Byun et al, 2010; Fuchs et al, 2012 and thresholds of activation in response to store depletion (Shaw et al, 2012) . Only the combined deletion of Stim1 and Stim2 genes completely abolishes SOCE. Deletion of Stim1 alone strongly, but incompletely reduces SOCE. By contrast, deletion of Stim2 alone has no effect on the peak of Ca 2þ influx but significantly impairs sustained SOCE (Oh-Hora et al, 2008) . Normal tumour rejection in Stim1 fl/fl Cd4Cre mice therefore indicates that moderate SOCE is sufficient for the cytolytic effector functions of CTLs and their ability to provide antitumour immunity in vivo. This might also explain why CD8 þ T cells from a patient with homozygous loss-offunction mutation in STIM1 and severely impaired SOCE showed normal cytotoxicity against CD3-coated L1210 target cells in vitro (Fuchs et al, 2012) . This is in contrast to impaired cytolytic function of human NK cells lacking functional ORAI1, the pore-forming subunit of the CRAC channel, which had a severe defect in killing L1210 and K562 tumour cells (Maul-Pavicic et al, 2011) . Similarly, STIM1-deficient murine NK cells showed defective cytotoxicity in vitro (Maul-Pavicic et al, 2011) , pointing to a potential difference in the SOCE requirements of CTLs and NK cells for their cytolytic function. Collectively, these data from STIM1, STIM1/STIM2 and ORAI1 deficient patients and mice demonstrate that SOCE is required for the cytotoxicity of CTLs, but that moderate levels of SOCE are sufficient for CTL function. Recent studies have demonstrated an important role for ORAI1 and STIM1 proteins in cancer cells and carcinogenesis. For instance, SOCE was shown to control the proliferation and apoptosis of cancer cells, promote tumour metastasis and regulate neovascularization [reviewed in (Bergmeier et al, 2013) ]. Dysregulated expression of ORAI1 and STIM1 genes was found in several types of cancer and has been linked to more aggressive forms of breast and cervical cancer (Chen et al, 2011; Yang et al, 2009 
MATERIALS AND METHODS
Mice
Stim1
fl/fl Cd4Cre and Stim1 fl/fl Stim2 fl/fl Cd4Cre (DKO) mice were described previously (Oh-Hora et al, 2008) . They were further crossed to OT-1 mice (stock # 003831) expressing a transgenic TCR specific for the SIINFEKL peptide of ovalbumin (Ova). OT-1 and CD45.1 (stock # 002014) mice were purchased from Jackson Laboratories (Bar Harbor, ME). Mice were maintained in a specific pathogen free barrier facility at New York University Langone Medical Center and used in accordance with protocols approved by the institutional animal care and use committee. 
Flow cytometry, antibodies and tetramers
Antibodies against the following proteins were purchased from eBiosciences (San Diego, CA): CD4 (GK1.5), CD8 (53-6.7), CD25 (eBio3C, PC61), CD107a (1D4B), FOXP3 (FJK-16s), TNF-a (MP6-XT22), IFN-g (XMG1.2), Perforin (eBioOMAK-D), Granzyme B (NGZB) and FasL (MFL3). Annexin V-FITC and Annexin V-eFluor 450 were from BD Bioscience (San Jose, CA). H-2Kb Ova SIINFEKL tetramers were generated by the MHC Tetramer Production Facility at Baylor College Medicine (Houston, TX). Intracellular cytokine staining was performed as described . Flow cytometry was conducted using a LSR II (BD Biosciences) and analysed using FlowJo software (TreeStar, Ashland, OR).
Immunohistochemistry
Tumours were excised, fixed in 4% formaldehyde overnight and embedded in paraffin. 5 mm sections were used for immunostaining as described (Nancy et al, 2012) . Briefly, tissues were incubated with biotinylated anti-CD3 antibody (2C11, 1:500, eBioscience) followed by horseradish peroxidase (HRP)-conjugated streptavidin (Jackson Immunoresearch, West Grove, PA). The antibody signal was amplified with biotin-tyramide (Perkin Elmer) and incubation with Alexa Fluor 594-conjugated Streptavidin (Invitrogen). Cell nuclei were counterstained with DAPI (Invitrogen). Epifluoresence images were acquired on an AxioImager M1 microscope and analyzed using AxioVision software (both Carl Zeiss Microimaging, Thornwood, NY). Images were uniformly processed to enhance signal intensity using ImageJ software (http://rsb. info.nih.gov/ij/). with R being the Fura-2 emission ratio 340/380 nm. Graphs were plotted using Graphpad Prism software. For some experiments, cells were pretreated for 14-18 h with the CRAC channel inhibitor BTP2 (N-(4-[3,5-bis(trifluoromethyl)-1H-pyrazol-1-yl]phenyl)-4-methyl-1,2,3-thiadiazole-5-carboxamide (EMD Millipore, Billerica, MA) at the indicated concentrations.
Adoptive CTL transfer
Ova-specific CTLs were generated by isolating splenocytes from the spleens of wildtype OT-1 mice and by stimulation of CD8 þ T cells with 0.75 mg/ml SIINFEKL peptide. CTLs were differentiated for 6-8 days as previously described (Budhu et al, 2010; McCarl et al, 2010) . Starting on Day 3, RPMI 1640 medium was supplemented with 100 U/ml human rIL-2 (NIH AIDS reagent program). On Day 8, CD8 þ CTLs were purified using a negative selection kit (Stemcell Technologies, Vancouver, Canada). For homing assays, CTLs were labelled with either 5 mM CellTracker Orange or CellTracker Violet (Invitrogen, Carlsbad, CA). 1 Â 10 6 CTLs were injected i.v. into wild-type C57BL/6 (CD45.1) mice either at the time of tumour cell injection or 7 days later. For some experiments, CTLs were incubated overnight with BTP2 (or DMSO) prior to injection to inhibit CRAC channels. 
Cytotoxicity and degranulation assays
Statistical Analyses
p Values were calculated using the two-tailed unpaired Student's t-test and Graphpad Prism software. All graphs show the average AE SEM.
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